DiaMedica Therapeutics (DMAC) Competitors $6.90 +0.04 (+0.51%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. HROW, JANX, COGT, SDGR, SNDX, ABCL, AMPH, STOK, TLRY, and EVOShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Harrow (HROW), Janux Therapeutics (JANX), Cogent Biosciences (COGT), Schrodinger (SDGR), Syndax Pharmaceuticals (SNDX), AbCellera Biologics (ABCL), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Tilray Brands (TLRY), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors Harrow Janux Therapeutics Cogent Biosciences Schrodinger Syndax Pharmaceuticals AbCellera Biologics Amphastar Pharmaceuticals Stoke Therapeutics Tilray Brands Evotec DiaMedica Therapeutics (NASDAQ:DMAC) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment. Do analysts prefer DMAC or HROW? DiaMedica Therapeutics currently has a consensus target price of $12.33, indicating a potential upside of 78.61%. Harrow has a consensus target price of $64.67, indicating a potential upside of 45.42%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Harrow 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is DMAC or HROW more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -78.99% -69.94% Harrow -4.49%-2.18%-0.35% Do institutionals and insiders have more ownership in DMAC or HROW? 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 7.3% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 15.2% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to DMAC or HROW? In the previous week, Harrow had 9 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 9 mentions for Harrow and 0 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.74 beat Harrow's score of 0.62 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Overall Sentiment DiaMedica Therapeutics Positive Harrow Positive Which has preferable earnings & valuation, DMAC or HROW? Harrow has higher revenue and earnings than DiaMedica Therapeutics. Harrow is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-10.01Harrow$199.61M8.24-$17.48M-$0.25-177.88 Which has more volatility and risk, DMAC or HROW? DiaMedica Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. SummaryHarrow beats DiaMedica Therapeutics on 9 of the 15 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$356.92M$3.14B$5.75B$10.34BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-10.0121.4376.8526.78Price / SalesN/A254.67451.7490.11Price / CashN/A45.4837.2260.63Price / Book7.279.6614.136.37Net Income-$24.44M-$53.02M$3.29B$271.28M7 Day Performance-5.15%0.54%0.13%1.50%1 Month Performance19.88%4.99%4.81%7.10%1 Year Performance67.19%11.22%88.55%29.88% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics2.0498 of 5 stars$6.91+0.5%$12.33+78.6%+57.9%$356.92MN/A-10.0120HROWHarrow2.978 of 5 stars$42.82+8.6%$64.67+51.0%-1.0%$1.46B$199.61M-171.28180High Trading VolumeJANXJanux Therapeutics2.6514 of 5 stars$23.56-2.0%$80.92+243.4%-52.6%$1.45B$10.59M-13.0930Analyst UpgradeGap UpCOGTCogent Biosciences2.8972 of 5 stars$12.41-2.0%$20.00+61.2%+17.5%$1.44BN/A-6.9780Positive NewsSDGRSchrodinger3.4513 of 5 stars$18.46-0.6%$27.83+50.8%-3.0%$1.37B$207.54M-7.44790Positive NewsSNDXSyndax Pharmaceuticals3.9295 of 5 stars$15.84+1.9%$39.22+147.6%-18.3%$1.34B$23.68M-4.07110ABCLAbCellera Biologics3.0475 of 5 stars$4.35-2.7%$8.00+83.9%+67.4%$1.34B$28.83M-7.91500News CoverageAMPHAmphastar Pharmaceuticals4.0314 of 5 stars$27.27-2.8%$31.60+15.9%-44.5%$1.30B$731.97M10.212,028STOKStoke Therapeutics3.8626 of 5 stars$23.40-0.3%$25.57+9.3%+50.4%$1.29B$199.89M27.53100TLRYTilray Brands3.0151 of 5 stars$1.18+5.4%$1.94+64.2%-34.3%$1.23B$210.48M-0.512,842EVOEvotec1.8793 of 5 stars$3.50+0.9%$5.40+54.3%+0.0%$1.23B$862.40M0.004,827News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Harrow Alternatives Janux Therapeutics Alternatives Cogent Biosciences Alternatives Schrodinger Alternatives Syndax Pharmaceuticals Alternatives AbCellera Biologics Alternatives Amphastar Pharmaceuticals Alternatives Stoke Therapeutics Alternatives Tilray Brands Alternatives Evotec Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMAC Stock Alerts